Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer

Journal of Oncology Practice

Volumn 9, Issue 5, 2013, Pages

  Speck, Rebecca M ^a   Sammel, Mary D ^a   Farrar, John T ^a   Hennessy, Sean ^a   Mao, Jun J ^a   Stineman, Margaret G ^a   DeMichele, Angela ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; PACLITAXEL;

ADULT; ALLERGIC REACTION; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERIPHERAL NEUROPATHY; RETROSPECTIVE STUDY;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MIDDLE AGED; PACLITAXEL; PENNSYLVANIA; PERIPHERAL NERVOUS SYSTEM DISEASES; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 84888226264     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2012.000863     Document Type: Article

References (28)

1. Wolf S, Barton D, Kottschade L, et al: Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies. Eur J Cancer 44: 1507-1515, 2008
2. Blumenthal DT: Assessment of neuropathic pain in cancer patients. Curr Pain Headache Rep 13: 282-287, 2009
3. Hausheer FH, Schilsky RL, Bain S, et al: Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33: 15-49, 2006 (Pubitemid 43214485)
4. Paice JA: Clinical challenges: Chemotherapy-induced peripheral neuropathy. Semin Oncol Nurs 25:S8-S19, 2009 (suppl 1)
5. Speck RM, DeMichele A, Farrar JT, et al: Scope of symptoms and selfmanagement strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients. Support Care Cancer 20: 2433-2439, 2012
6. Chang J: Chemotherapy dose reduction and delay in clinical practice: Evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer 36:S11-S14, 2000 (suppl 1)
7. US Cancer Statistics Working Group: United States cancer statistics: 1999- 2009 incidence and mortality. http://www.cdc.gov/uscs
8. Cavaletti G, Marmiroli P: The role of growth factors in the prevention and treatment of chemotherapy-induced peripheral neurotoxicity. Curr Drug Saf 1:35- 42, 2006
9. Cavaletti G, Frigeni B, Lanzani F, et al: Chemotherapy-induced peripheral neurotoxicity assessment: A critical revision of the currently available tools. Eur J Cancer 46: 479-494, 2010
10. Cavaletti G, Marmiroli P: Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol 6: 657-666, 2010
11. Dunlap B, Paice JA: Chemotherapy-induced peripheral neuropathy: A need for standardization in measurement. J Support Oncol 4: 398-399, 2006 (Pubitemid 44541015)
12. Basch E, Artz D, Dulko D, et al: Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol 23: 3552-3561, 2005
13. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982 (Pubitemid 13149996)
14. Mayers C, Panzarella T, Tannock IF: Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 91: 2246-2257, 2001 (Pubitemid 32552809)
15. Cottin V, Arpin D, Lasset C, et al: Small-cell lung cancer: Patients included in clinical trials are not representative of the patient population as a whole. Ann Oncol 10: 809-815, 1999 (Pubitemid 29367998)
16. Fosså SD, Skovlund E: Selection of patients may limit the generalizability of results from cancer trials. Acta Oncol 41: 131-137, 2002 (Pubitemid 34557072)
17. Kuroi K, Shimozuma K, Ohashi Y, et al: A questionnaire survey of physicians' perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer. Jpn J Clin Oncol 38: 748-754, 2008
18. Kahan Z, Uhercsak G, Hajnal-Papp R, et al: Dose-dense sequential adriamycin- paclitaxel-cyclophosphamide chemotherapy is well tolerated and safe in high-risk early breast cancer. Oncology 68: 446-453, 2005 (Pubitemid 41160976)
19. Mainwaring P, Shannon C: A phase II study of dose-dense chemotherapy (doxorubicin (A), cyclophosphamide (C), paclitaxel (T), gemcitabine (G)) supported by pegfilgrastim (P) and darbepoetin-alfa (D) for patients with high-risk early stage breast cancer (ICANDO). J Clin Oncol 25:18s, 2007 (suppl; abstr 11068)
20. Madarnas Y, Sawka CA, Franssen E, et al: Are medical oncologists biased in their treatment of the large woman with breast cancer? Breast Cancer Res Treat 66: 123-133, 2001 (Pubitemid 32521418)
21. Bonadonna G, Valagussa P, Moliterni A, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. N Engl J Med 332: 901-906, 1995
22. DuBois D, DuBois E: A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 17: 863-871, 1916
23. Schneider BP, Li L, Miller K, et al: Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103. J Clin Oncol 29:15s, 2011 (suppl; abstr 1000)
24. Schneider BP, Zhao F, Wang M, et al: Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol 30: 3051-3057, 2012
25. Gogas H, Shapiro F, Aghajanian C, et al: The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. Gynecol Oncol 61: 22-26, 1996 (Pubitemid 26108524)
26. Maldonado G, Greenland S: Simulation study of confounder-selection strategies. Am J Epidemiol 138: 923-936, 1993 (Pubitemid 24002359)
27. Foote M: The importance of planned dose of chemotherapy on time: Do we need to change our clinical practice? Oncologist 3: 365-368, 1998 (Pubitemid 28485579)
28. Stubblefield MD, Burstein HJ, Burton AW, et al: NCCN task force report: Management of neuropathy in cancer. J Natl Compr Canc Netw 7:S1-S26, 2009; quiz S27-S28 (suppl 5)